Study Name Principal Investigator
(Asteroid 6) An open-label, parallel-group, randomized, multicenter study to assess the safety and efficacy of vilaprisan in subjects with uterine fibroids versus standard of care Theisen, John Graham
(Bayer Elagolix) A randomized, double-blind, open for active comparator, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of three different doses of P2X3 antagonist (BAY 1817080) versus placebo and elagolix 150 mg in women with symptomatic endometriosis Brakta, Soumia
(Edelweiss) A Phase 3 multicenter, randomized, double-blind, placebo-controlled, clinical study to assess the efficacy and safety of linzagolix in subjects with moderate to severe endometriosis-associated pain Brakta, Soumia
(MK7339-002) A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer Nayak-Kapoor, Asha
(SASS) Randomized trial of Single-incision versus Retropubic Mid-Urethral Sling (Solyx™) for Concomitant Management of Stress Urinary Incontinence during Minimally Invasive Sacrocolpopexy Henley, Barbara
1951-CL-0101 A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Ghamande, Sharad
4010-03-001 / ENGOT EN-6 / GOG-3031: A phase 3, randomized, double-blind, multicenter study of dostarlimab (TSR-042) plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in patients with recurrent or primary advanced endometrial cancer (RUBY) Ghamande, Sharad
A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer Ghamande, Sharad
A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed By Electroporation With Cellectra™ 5PSP For The Treatment Of HPV-16 And/Or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) Of The Cervix Rungruang, Bunja
A011106; ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III study Ghamande, Sharad
A011401; Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer Ghamande, Sharad
A011502: A randomized phase III double blinded placebo-controlled trial of aspirin as adjuvant therapy for node-positive, HER2 negative breast cancer: the ABC trial Ghamande, Sharad
ADXS001-04: Phase 1-2 Study of MEDI4736 Alone or In Combination with ADXS11-001 In Recurrent/Persistent or Metastatic Cervical or HPV+ Head & Neck Cancer Ghamande, Sharad
AVA-CIT-330: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Active Non-Hematological Cancer Ghamande, Sharad
Breast and Ovarian Cancer in African American Women: Intergenerational Cancer Prevention Vernon, Marlo
C-145-04: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma Ghamande, Sharad
CDX1140-01: A Phase 1 Study of CDX-1140, a Fully Human Agonist anti-CD40 Monoclonal Antibody, as Monotherapy or in Combination in Patients with Advanced Malignancies Kota, Vamsi
CO-338-043: ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Ghamande, Sharad
D081RC00001 A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O) Ghamande, Sharad
Development of a patient centered primary and secondary prevention intervention for breast and ovarian cancer in African American women Vernon, Marlo
Developmental Gene Discovery Project: Mapping and Identifying New Genes in Uterine and Vaginal Development; Identifying New Genes Causing Birth Defects in Children Layman, Lawrence
EA1131 A Randomized Phase III Post Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy Ghamande, Sharad
EP0057-201: A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 – platinum resistant disease and are PARP inhibitor naïve; Cohort 2 – had at least 2 prior lines of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenance. Ghamande, Sharad
GCT1015-05/GOG 3024: A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax® -TF -ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer Ghamande, Sharad
Genetics of Delayed Puberty/ Genes Important in Puberty, Dual Functions of WDR11 in the Pathogenesis of Hypogonadotrophic Hypogonadism Layman, Lawrence
Georgetown STUDY00003849: A phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer Ghamande, Sharad
Implementing HPV DNA Self-Collection to Increase Rates of Cervical Cancer Screening In Transgender Men Theisen, John
INCMGA 0012-204: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) Ghamande, Sharad
Kadmon KD025-013: A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study) Kota, Vamsi
MER-XMT-1536-1/GOG 3048: A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b Ghamande, Sharad
MORAb-003-011: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer Ghamande, Sharad
MORAb-202-G000-201: A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor Types Ghamande, Sharad
MS200647_0046 Safety Study of Bintrafusp alfa in Combination with Other Anti-cancer Therapies in Participants with Locally Advanced or Advanced Cervical Cancer Ghamande, Sharad
MS201943-0029: A Phase Ib, Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination with Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants with PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Ghamande, Sharad
NRG-GY009; A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer Ghamande, Sharad
ONT-380-206: Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma Ghamande, Sharad
SGNTV-002 - Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen Ghamande, Sharad
SGNTV-003/GOG 3057: A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer Ghamande, Sharad
TESARO 4010-01-001: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors Ghamande, Sharad
Understanding the Genetic Basis of Transgender Identity Layman, Lawrence
WO42017 - A PHASE II, SAFETY, AND EFFICACY STUDY OF TIRAGOLUMAB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY IN PATIENTS WITH METASTATIC AND/OR RECURRENT PD-L1 POSITIVE CERVICAL CANCER Ghamande, Sharad
RESEARCH. INNOVATION. DISCOVERY.